Affordable Access

Publisher Website

Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy

Authors
Journal
Journal of Hepatology
0168-8278
Publisher
Elsevier
Publication Date
Volume
50
Issue
4
Identifiers
DOI: 10.1016/j.jhep.2008.10.033
Keywords
  • Hepatitis B Treatment
  • Entecavir
  • Adefovir
  • Suboptimal Response
  • Antiviral Drug Resistance
Disciplines
  • Biology
  • Medicine

Abstract

Background/Aims We investigated the efficacy of entecavir in lamivudine-experienced and -naïve patients with persistently high HBV DNA during adefovir treatment. Methods Fourteen chronic hepatitis B patients (57% lamivudine-experienced) with a viral load above 5 log 10 copies/mL after 12 months of adefovir therapy and thereafter were treated with entecavir 1 mg daily. Results During a median follow-up of 15 months (range: 8–23 months) one of six lamivudine–naïve and none of the eight lamivudine-experienced patients achieved undetectable HBV DNA (<373 copies/mL). HBeAg loss occurred in none of the subjects. Two lamivudine-experienced patients demonstrated the rtM204I mutation; no other entecavir-resistant substitutions were detected (rtI169, rtT184, rtS202, and rtM250). Two of three patients with genotypic adefovir resistance at baseline demonstrated a rapid virologic response to entecavir, but undetectable HBV DNA was not achieved. To attain a better antiviral response the dosage of entecavir was increased to 2 mg daily in two patients, resulting in further viral load decline for both of them. Conclusions Entecavir monotherapy dosed at 1 mg resulted in a slow reduction of viral load in both lamivudine-experienced and -naïve patients with persistently high HBV DNA during adefovir therapy. Increasing the dosage of entecavir led to further HBV DNA decline.

There are no comments yet on this publication. Be the first to share your thoughts.